Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, has been awarded a $659,538 Lisa Dean Moseley Foundation grant to further her team’s triple-negative breast cancer research.
Dr. Sims-Mourtada and her team investigate the role of cells immediately around a tumor and their impact on triple-negative breast cancer, which is resistant to current therapies and disproportionately affects premenopausal women and African American women.
“The Moseley Foundation’s grant will help our breast cancer research team address a pressing concern for Delaware, which has the highest rate of triple-negative breast cancer in the nation,” said Nicholas J. Petrelli, M.D., medical director of the cancer center, in a press statement.
Before receiving the grant, Dr. Sims-Mourtada’s team found that an anti-inflammatory drug that is used to treat rheumatoid arthritis may have the potential slow the growth of cancer stem cells and triple-negative breast cancer tumors. They will now further research the relationship between cancer stem cells and inflammation by comparing pre- and post-chemotherapy breast tissue.
Delaware Department of Agriculture is offering grants for specialty agtech projects
Is your business lacking in energy efficiency? There are state grants for that
University of Delaware researcher receives $250K grant for new biotherapies
Energize Delaware grant apps are now open
Sign-up for daily news updates from Technical.ly Delaware